This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bemer, P.
Right arrow Articles by Drugeon, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bemer, P.
Right arrow Articles by Drugeon, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 3025-3029, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.3025-3029.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of a New Lipopeptide, HMR 1043, against Susceptible and Resistant Gram-Positive Isolates

Pascale Bemer,1* Marie-Emmanuelle Juvin,1 Andre Bryskier,2 and Henri Drugeon1

Department of Microbiology, Hôtel-Dieu University Hospital, Nantes,1 Clinical Pharmacology of Anti-Infectives, Aventis Pharma, Hoechst Marion Roussel, Romainville, France2

Received 18 March 2002/ Returned for modification 10 May 2002/ Accepted 6 June 2003


arrow
ABSTRACT
 
The purpose of this study was to compare the activity of HMR 1043 with those of daptomycin and teicoplanin against gram-positive isolates. Susceptibility tests were performed for 52 strains, 26 parental strains, including staphylococcal, streptococcal, enterococcal, and listerial strains, and 26 HMR 1043-resistant mutants obtained from parental strains by using the Szybalski method. Agar dilution and disk diffusion susceptibility tests were performed by the procedures outlined by the NCCLS. HMR 1043 demonstrated good activity against susceptible and resistant gram-positive bacteria. The activity of HMR 1043 in vitro was less influenced by the presence of calcium ions than that of daptomycin. Susceptibility test breakpoints were not defined because of the poor correlation coefficients obtained with the different disks tested.


arrow
TEXT
 
HMR 1043 is a new antibiotic belonging to the class of cyclic lipopeptides that includes daptomycin (6). The structure of HMR 1043 is shown in Fig. 1. These drugs are being developed for the treatment of severe infections due to antibiotic-resistant gram-positive cocci. Daptomycin is active against susceptible and resistant gram-positive isolates, such as vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate staphylococci, and penicillin-resistant pneumococci (2, 4, 8, 11, 12). The antibacterial activity of daptomycin requires the presence of calcium cations. Previous studies have recommended a calcium supplementation of 50 mg/liter for broth microdilution susceptibility tests (1, 5, 7) and of 9 mM (200 mg/liter) for agar dilution susceptibility tests (3).



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 1. Structure of HMR 1043.

The objective of this study was to compare the activity of HMR 1043 with those of daptomycin and teicoplanin against susceptible and resistant gram-positive isolates, to investigate the effect of calcium supplementation, and to interpret the zone size obtained with different HMR 1043 disks. The Szybalski method (13) was used for the preliminary selection of mutants, because of the rarity of truly resistant gram-positive strains.

The 26 parental strains included 18 clinical and 8 reference isolates: 5 Staphylococcus aureus strains (including 1 with intermediate resistance to teicoplanin and 1 vancomycin-intermediate Staphylococcus aureus strain), 4 Staphylococcus epidermidis strains (including 1 resistant to teicoplanin), 2 Staphylococcus haemolyticus strains (including 1 resistant to teicoplanin), 3 Enterococcus faecalis strains (1 possessing the vanA gene and 1 possessing the vanB gene), 3 Enterococcus faecium strains (1 with the vanA gene and 1 with the vanB gene), 2 Listeria monocytogenes strains, 3 Streptococcus pneumoniae strains (including 1 penicillin resistant), 2 Streptococcus pyogenes strains, and 2 Streptococcus agalactiae strains.

HMR 1043-resistant mutants were selected by plating 109 CFU of overnight cultures of the 26 parental strains grown in Mueller-Hinton (MH) medium on MH agar containing an HMR 1043 gradient up to 32 times the MIC (13). Spontaneously resistant colonies appeared after incubation at 37°C for 24 to 48 h. The colony grown in the highest drug concentration was taken as the mutant strain. Susceptibility tests were performed for the 52 strains, the 26 parental strains and 26 mutants.

HMR 1043 and teicoplanin were kindly provided by Aventis (Romainville, France), and daptomycin was provided by Lilly Research Laboratories (Indianapolis, Ind.). HMR 1043, daptomycin, and teicoplanin concentrations ranged from 0.0038 to 16 µg/ml. Disks with 7.5, 15, 30, 60, and 120 µg of HMR 1043 were prepared. Agar dilution and disk diffusion susceptibility tests were performed by the procedures outlined by the National Committee for Clinical Laboratory Standards (9, 10), with MH agar supplemented with 5% whole sheep blood when streptococcal and listerial strains were tested. The following media were used: base MH agar containing 100 mg of Ca2+ per liter and MH agar supplemented with up to 207 mg (9 mM) of Ca2+ per liter (CSMH) from a 20-g/liter CaCl2 solution. MICs and inhibition zone diameters were read after 18 h of incubation at 37°C.

Comparative antimicrobial activity. The comparative MICs of HMR 1043, daptomycin, and teicoplanin are shown in Table 1. The activity of HMR 1043 was not influenced by the resistance of staphylococci to methicillin or teicoplanin, the resistance of pneumococci to penicillin, or the resistance of enterococci to vancomycin (vanA or vanB type). HMR 1043 was two- to eightfold less active than daptomycin against listerial isolates. Mutants selected from staphylococci intermediate or resistant to teicoplanin were 4- to 16-fold less susceptible than the parental strains (HMR 1043 MICs, 4 to 8 µg/ml). MICs of daptomycin for parental and mutant streptococcal and listerial strains were identical. Mutants selected from the Staphylococcus epidermidis clinical strains were twofold to eightfold more resistant than the parental strains, with daptomycin MICs of <=2 µg/ml; MICs of teicoplanin for parental and mutant strains were comparable. Streptococci were more susceptible to teicoplanin than staphylococci.


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro activity of HMR 1043 and other agents on parental and mutant strainsa

Comparisons of HMR 1043, daptomycin, and teicoplanin MICs by regression statistics yielded poor correlation coefficients as follows: HMR 1043 versus daptomycin, r = 0.51; HMR 1043 versus teicoplanin, r = 0.02. These data imply that HMR 1043 is more related to daptomycin than to teicoplanin.

Effect of calcium on activity. The comparative MICs of HMR 1043 and daptomycin tested on MH agar and on CSMH are shown in Table 1. The addition of calcium had little effect on HMR 1043 activity: MICs generally varied no more than twofold. Daptomycin MICs determined in CSMH were fourfold lower than those obtained in unsupplemented MH agar: HMR 1043 versus daptomycin, r = 0.36.

Disk diffusion tests. Correlations among HMR 1043 MICs and zone diameters around 7.5-,15-, 30-, 60-, and 120-µg HMR 1043 disks on MH agar and CSMH are shown in Fig. 2 and 3, respectively. The correlation coefficients for the four different disks were poor (r range, 0.12 to 0.58) and lower when disk diffusion tests were performed in CSMH (r range, 0.01 to 0.39). The best correlation was obtained with the 7.5-µg disk on MH agar (r = 0.58) versus 0.39 on CSMH. Scattergrams of the disk zone diameters and HMR 1043 MICs determined in MH agar and in CSMH are shown in Fig. 4 and 5, respectively. Therefore, zone diameters remained small: a MIC of 1 µg/ml was correlated with a zone diameter of 16 mm, and a MIC of 4 µg/ml was correlated with a zone diameter of 11 mm (Fig. 4). Disks with 7.5 µg of HMR 1043 performed better, with zone diameters very similar to those determined in MH agar.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2. Correlations between HMR 1043 MICs and zone diameters around 7.5-, 15-, 30-, 60-, and 120-µg HMR 1043 disks on MH agar.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 3. Correlations between HMR 1043 MICs and zone diameters around 7.5-, 15-, 30-, 60-, and 120-µg HMR 1043 disks on CSMH.



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 4. Scattergram showing correlations between HMR 1043 MICs and zone diameters around 7.5-µg HMR 1043 disks on MH agar.



View larger version (8K):
[in this window]
[in a new window]
  		FIG. 5. Scattergram showing correlations between HMR 1043 MICs and zone diameters around 7.5-µg HMR 1043 disks on CSMH.

HMR 1043 demonstrated good activity against susceptible and resistant gram-positive bacteria. The activity of HMR 1043 in vitro is less influenced by the presence of calcium ions than that of daptomycin. The activities of HMR 1043 and daptomycin against staphylococcal and streptococcal parental strains were similar, but daptomycin remains more active than HMR 1043 against enterococcal and listerial strains. Mutants selected from teicoplanin-intermediate or -resistant coagulase-negative staphylococci were 8-fold to 16-fold more resistant to HMR 1043 than their parental strains (MICs >= 4 µg/ml) and remained susceptible to daptomycin (MICs <= 2 µg/ml). Selection of in vitro susceptibility test breakpoints for HMR 1043 was difficult because of the poor correlation coefficients obtained with the different disks tested.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Hôtel-Dieu University Hospital, 9, Quai Moncousu, 44093 Nantes cedex 01, France. Phone: (33) 2 40 08 39 85. Fax: (33) 2 40 16 54 55. E-mail: pascale.bemer{at}chu-nantes.fr. Back


arrow
REFERENCES
 
    1
  1. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.[Abstract/Free Full Text]
    2. 2
  2. Coudron, P. E., J. L. Johnson, and G. L. Archer. 1987. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis. J. Antimicrob. Chemother. 20:505-511.[Abstract/Free Full Text]
    3. 3
  3. Ehlert, F., and H. C. Neu. 1987. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur. J. Clin. Microbiol. 6:84-90.[CrossRef][Medline]
    4. 4
  4. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.[Abstract/Free Full Text]
    5. 5
  5. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.[CrossRef][Medline]
    6. 6
  6. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31:625-629.[Abstract/Free Full Text]
    7. 7
  7. Louie, A., A. L. Baltch, W. J. Ritz, R. P. Smith, and M. Asperilla. 1993. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 39:302-310.[Medline]
    8. 8
  8. Mobarakai, N., J. M. Quale, and D. Landman. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.[Abstract/Free Full Text]
    9. 9
  9. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial susceptibility tests, 6th ed. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    10. 10
  10. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    11. 11
  11. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.[Abstract/Free Full Text]
    12. 12
  12. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.[Abstract/Free Full Text]
    13. 13
  13. Szybalski, W. 1952. Microbial selection. I. Gradient plate technique for study of bacterial resistance. Science 116:46-48.

Antimicrobial Agents and Chemotherapy, September 2003, p. 3025-3029, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.3025-3029.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Raad, I. I., Hanna, H. A., Boktour, M., Chaiban, G., Hachem, R. Y., Dvorak, T., Lewis, R., Murray, B. E. (2005). Vancomycin-Resistant Enterococcus faecium: Catheter Colonization, esp Gene, and Decreased Susceptibility to Antibiotics in Biofilm. Antimicrob. Agents Chemother. 49: 5046-5050 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bemer, P.
Right arrow Articles by Drugeon, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bemer, P.
Right arrow Articles by Drugeon, H.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»